Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $365.78 billion. The enterprise value is $412.55 billion.
| Market Cap | 365.78B |
| Enterprise Value | 412.55B |
Important Dates
The next confirmed earnings date is Thursday, October 29, 2026, before market open.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Sep 15, 2026 |
Share Statistics
Merck & Co. has 2.47 billion shares outstanding. The number of shares has decreased by -1.92% in one year.
| Current Share Class | 2.47B |
| Shares Outstanding | 2.47B |
| Shares Change (YoY) | -1.92% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 81.52% |
| Float | 2.46B |
Valuation Ratios
The trailing PE ratio is 116.26 and the forward PE ratio is 17.19. Merck & Co.'s PEG ratio is 3.06.
| PE Ratio | 116.26 |
| Forward PE | 17.19 |
| PS Ratio | 5.48 |
| Forward PS | 5.34 |
| PB Ratio | 8.71 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 22.69 |
| P/OCF Ratio | 18.25 |
| PEG Ratio | 3.06 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.24, with an EV/FCF ratio of 25.60.
| EV / Earnings | 129.61 |
| EV / Sales | 6.18 |
| EV / EBITDA | 14.24 |
| EV / EBIT | 17.51 |
| EV / FCF | 25.60 |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 1.28.
| Current Ratio | 1.32 |
| Quick Ratio | 0.74 |
| Debt / Equity | 1.28 |
| Debt / EBITDA | 1.84 |
| Debt / FCF | 3.36 |
| Interest Coverage | 13.47 |
Financial Efficiency
Return on equity (ROE) is 6.96% and return on invested capital (ROIC) is 14.05%.
| Return on Equity (ROE) | 6.96% |
| Return on Assets (ROA) | 11.87% |
| Return on Invested Capital (ROIC) | 14.05% |
| Return on Capital Employed (ROCE) | 23.01% |
| Weighted Average Cost of Capital (WACC) | 5.01% |
| Revenue Per Employee | $887,587 |
| Profits Per Employee | $42,307 |
| Employee Count | 75,000 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.51 |
Taxes
In the past 12 months, Merck & Co. has paid $2.78 billion in taxes.
| Income Tax | 2.78B |
| Effective Tax Rate | 46.72% |
Stock Price Statistics
The stock price has increased by +86.21% in the last 52 weeks. The beta is 0.23, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +86.21% |
| 50-Day Moving Average | 140.38 |
| 200-Day Moving Average | 121.67 |
| Relative Strength Index (RSI) | 56.00 |
| Average Volume (20 Days) | 9,442,585 |
Short Selling Information
The latest short interest is 30.29 million, so 1.23% of the outstanding shares have been sold short.
| Short Interest | 30.29M |
| Short Previous Month | 28.28M |
| Short % of Shares Out | 1.23% |
| Short % of Float | 1.23% |
| Short Ratio (days to cover) | 2.74 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $66.57 billion and earned $3.17 billion in profits. Earnings per share was $1.27.
| Revenue | 66.57B |
| Gross Profit | 50.53B |
| Operating Income | 23.48B |
| Pretax Income | 5.95B |
| Net Income | 3.17B |
| EBITDA | 28.87B |
| EBIT | 23.48B |
| Earnings Per Share (EPS) | $1.27 |
Balance Sheet
The company has $7.14 billion in cash and $53.91 billion in debt, with a net cash position of -$46.77 billion or -$18.96 per share.
| Cash & Cash Equivalents | 7.14B |
| Total Debt | 53.91B |
| Net Cash | -46.77B |
| Net Cash Per Share | -$18.96 |
| Equity (Book Value) | 41.98B |
| Book Value Per Share | 16.99 |
| Working Capital | 8.95B |
Cash Flow
In the last 12 months, operating cash flow was $19.97 billion and capital expenditures -$3.90 billion, giving a free cash flow of $16.06 billion.
| Operating Cash Flow | 19.97B |
| Capital Expenditures | -3.90B |
| Depreciation & Amortization | 5.39B |
| Net Borrowing | 18.69B |
| Free Cash Flow | 16.06B |
| FCF Per Share | $6.51 |
Margins
Gross margin is 75.90%, with operating and profit margins of 35.28% and 4.77%.
| Gross Margin | 75.90% |
| Operating Margin | 35.28% |
| Pretax Margin | 8.94% |
| Profit Margin | 4.77% |
| EBITDA Margin | 43.37% |
| EBIT Margin | 35.28% |
| FCF Margin | 24.13% |
Dividends & Yields
This stock pays an annual dividend of $3.40, which amounts to a dividend yield of 2.29%.
| Dividend Per Share | $3.40 |
| Dividend Yield | 2.29% |
| Dividend Growth (YoY) | 4.94% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 267.12% |
| FCF Payout Ratio | 52.22% |
| Buyback Yield | 1.92% |
| Shareholder Yield | 4.22% |
| Earnings Yield | 0.87% |
| FCF Yield | 4.41% |
Analyst Forecast
The average price target for Merck & Co. is $152.96, which is 3.17% higher than the current price. The consensus rating is "Buy".
| Price Target | $152.96 |
| Price Target Difference | 3.17% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 4.77% |
| EPS Growth Forecast (3Y) | 5.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 17, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Feb 17, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Merck & Co. has an Altman Z-Score of 3.6 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.6 |
| Piotroski F-Score | 4 |